Products & Services · Percent Change (as a percent)
RYBREVANT + LAZCLUZE — Percent Change (as a percent)
Johnson & Johnson RYBREVANT + LAZCLUZE — Percent Change (as a percent) decreased by 17.1% to 82.7% in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ3 2025
Last reportedQ1 2026Apr 22, 2026
How to read this metric
An increase indicates strong market uptake and successful commercial execution for these specific oncology treatments, while a decrease may signal slowing demand, increased competition, or market saturation.
Detailed definition
This metric measures the period-over-period percentage growth in revenue generated by the combined Rybrevant and Lazcluz...
Peer comparison
Comparable to revenue growth rates for specific high-growth oncology or specialty pharmaceutical franchises at peer biopharmaceutical companies.
Metric ID:
jnj_segment_rybrevant_lazcluze_percent_change_as_a_percentHistorical Data
2 periods
| Q3 '25 | Q1 '26 | |
|---|---|---|
| Value | 99.7% | 82.7% |
| QoQ Change | — | -17.1% |
Range82.7% – 99.7%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's rybrevant + lazcluze — percent change (as a percent)?
- Johnson & Johnson (JNJ) reported rybrevant + lazcluze — percent change (as a percent) of 82.7% in Q1 2026.
- What does rybrevant + lazcluze — percent change (as a percent) mean?
- The percentage growth rate of revenue from the Rybrevant and Lazcluze oncology product line.